Duration questions
The questions tend to ask “how long?” The answers depend on what was measured and whether treatment was tested at all.
Does tesamorelin fat loss last after stopping?
In the 52-week program in adults with HIV and abdominal fat accumulation, visceral fat stayed reduced with continued treatment and reaccumulated after discontinuation. I regard withdrawal as indispensable to the account of this benefit. It makes a lasting reset an inaccurate description of that result.
Daily NAD+ safety
The 8-week NR trial in healthy overweight adults found no significant adverse-event difference from placebo. NR is a precursor used to make NAD+. That result cannot establish years of safety, and it cannot assess NAD+ taken by a different route. The word “daily” prompts another duration question: daily for how long?
MOTS-c onset in humans
Human treatment studies here supply no validated onset, half-life or duration of benefit for administered MOTS-c. The mouse exercise experiments and human dialysis blood-level cohort addressed different questions. A timetable borrowed from mice would give a human certainty the evidence has not earned.
Does lower fat mean longer life?
The tesamorelin trial synthesis measured changes in visceral, trunk and liver fat in HIV-associated lipodystrophy. Those measurements establish body-composition findings. Extra years would require survival evidence in the relevant population. I value the fat result while leaving that much larger question open.
Semaglutide composite outcomes
The SELECT cardiovascular trial included adults with established cardiovascular disease and overweight or obesity, without diabetes. The FLOW kidney trial included people with type 2 diabetes and chronic kidney disease. Both reduced their respective combined outcomes versus placebo. Each composite groups several events. An overall reduction establishes a benefit for that combined measure; individual components require their own results. General life extension in healthy people remains unproved.
Anecdotes and duration
Accounts of appetite, weight changes or adverse symptoms can describe experiences that matter to people. They are anecdotal accounts, not clinical evidence, and cannot establish what caused a change or how often it occurs. An unobserved period in a trial remains unobserved; personal accounts cannot supply a treatment schedule.